Detalhe da pesquisa
1.
Heterogenous improvements in endothelial function by sub-blood pressure lowering doses of ARBs result in major anti-aortic root remodeling effects.
Nitric Oxide
; 131: 18-25, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36565741
2.
Thermoneutral Housing and a Western Diet Combination Exacerbates Dysferlin-Deficient Muscular Dystrophy.
Muscle Nerve
; 66(4): 513-522, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35859452
3.
Humanization of the mdx Mouse Phenotype for Duchenne Muscular Dystrophy Modeling: A Metabolic Perspective.
J Neuromuscul Dis
; 10(6): 1003-1012, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37574742
4.
Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice.
Skelet Muscle
; 12(1): 25, 2022 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36447272
5.
Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties.
Vascul Pharmacol
; 147: 107112, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36179789
6.
Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.
PLoS One
; 14(8): e0220903, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31404091